Introduction Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a pivotal test in lung cancer staging and diagnosis, mandating robust audit and performance monitoring of EBUS services. We present the first regional cancer alliance EBUS performance audit against the new National EBUS specification. Methods Across the five EBUS centres in the Greater Manchester Cancer Alliance, data are recorded at the point of procedure, when pathological results are available and at 6 months postprocedure to review any further pathological sampling (eg, at surgical resection) and the outcome of clinical–radiological follow-up. Outcomes across all five centres were compared with national standards for all lung cancer EBUS procedures from 01 January 2017 to 31 December 2018. Results 1899 lung cancer staging or diagnostic EBUS procedures were performed across the five centres during the study period; 1309 staging EBUS procedures and 590 diagnostic EBUS procedures. Major complications were seen in six cases (<1%). All five trusts demonstrated performance above that set national standards in key metrics for both staging and diagnostic EBUS, however the provision of adequate tissue for predictive marker testing was below national standards at one trust. Across Greater Manchester, 72% and 64% of patients had their EBUS procedure performed within 7 days of referral in 2017 and 2018, respectively. Only one out of five trusts met the national targets of >85% of procedures performed within 7 days of referral. Conclusion The National EBUS service specification is an important framework to drive the quality of EBUS services across the UK. Our data provide assurance of appropriate performance and safety while also highlighting specific areas for attention that can be addressed with the support of the cancer alliance. All data relevant to the study are included in the article or uploaded as supplemental information.

中文翻译：

---

用于肺癌分期和诊断的 EBUS 性能监测：根据新的国家标准审核大曼彻斯特 EBUS 服务

简介 支气管内超声引导下经支气管针吸活检 (EBUS-TBNA) 是肺癌分期和诊断的关键测试，强制要求对 EBUS 服务进行稳健的审计和性能监测。我们针对新的国家 EBUS 规范提出了第一个区域癌症联盟 EBUS 性能审计。方法 在大曼彻斯特癌症联盟的五个 EBUS 中心，数据在手术点、病理结果可用时和手术后 6 个月记录数据，以审查任何进一步的病理取样（例如，在手术切除时）和临床结果——放射学随访。从 2017 年 1 月 1 日到 2018 年 12 月 31 日，所有五个中心的结果与所有肺癌 EBUS 程序的国家标准进行了比较。结果 在研究期间，五个中心进行了 1899 例肺癌分期或诊断性 EBUS 手术；1309 个分期 EBUS 程序和 590 个诊断 EBUS 程序。6 例 (<1%) 出现严重并发症。所有五个信托的表现都高于为分期和诊断 EBUS 设定的关键指标的国家标准，但是为预测标记测试提供的足够组织低于一个信托的国家标准。在大曼彻斯特，2017 年和 2018 年，分别有 72% 和 64% 的患者在转诊后 7 天内进行了 EBUS 手术。只有五分之一的信托达到了在转介后 7 天内执行的程序的 85% 以上的国家目标。结论 国家 EBUS 服务规范是推动英国 EBUS 服务质量的重要框架。我们的数据为适当的性能和安全性提供了保证，同时还突出了可以在癌症联盟的支持下解决的特定关注领域。与研究相关的所有数据都包含在文章中或作为补充信息上传。